Wang Yi, Ma Xibo, Chai Wei, Tian Jie
Department of Orthopedics, Chinese PLA General Hospital, Beijing 100853, China.
CAS Key Laboratory of Molecular Imaging, Institute of Automation, Chinese Academy of Sciences, Beijing 100190, China.
Stem Cells Int. 2019 Jan 8;2019:8914569. doi: 10.1155/2019/8914569. eCollection 2019.
The last couple of decades have seen brilliant progress in stem cell therapies, including native, genetically modified, and engineered stem cells, for osteonecrosis of the femoral head (ONFH). In vitro studies evaluate the effect of endogenous or exogenous factor or gene regulation on osteogenic phenotype maintenance and/or differentiation towards osteogenic lineage. The preclinical and clinical outcomes accelerate the clinical translation. Bone marrow mesenchymal stem cells and adipose-derived stem cells have demonstrated better effects in the treatment of femoral head necrosis. Various materials have been used widely in the ONFH treatment in both preclinical and clinical trials. In a word, in vivo and multiscale efforts are expected to overcome obstacles in the approaches for treating ONFH and provide clinical relevance and commercial strategies in the future. Therefore, we will discuss the above aspects in this paper and present our opinions.
在过去几十年中，干细胞疗法在治疗股骨头缺血性坏死（ONFH）方面取得了显著进展，包括使用天然、基因改造和工程化的干细胞。体外研究评估内源性或外源性因子或基因调控对成骨表型维持和/或向成骨谱系分化的影响。临床前和临床结果加速了临床转化。骨髓间充质干细胞和脂肪来源的干细胞在治疗股骨头坏死方面已显示出更好的效果。在临床前和临床试验中，各种材料已广泛应用于ONFH治疗。总之，预计体内和多尺度研究将克服ONFH治疗方法中的障碍，并在未来提供临床相关性和商业策略。因此，我们将在本文中讨论上述方面并提出我们的观点。
